ELOX — Eloxx Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $0.67m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Directors
- Tomer Kariv NEC (60)
- Sumit Aggarwal PRE (49)
- Daniel Geffken CFO (64)
- Ali Hariri OTH
- Vijay Modur OTH (54)
- Zafrira Avnur IND (70)
- Ran Nussbaum IND (48)
- Rajesh Parekh IND (61)
- Steven Rubin IND (60)
- Jasbir Seehra IND (65)
- Gadi Veinrib IND (42)
- Alan Walts IND (61)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- September 30th, 1999
- Public Since
- November 23rd, 2012
- No. of Shareholders
- 90
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 3,143,390
- Address
- 480 ARSENAL WAY, SUITE 130, WATERTOWN, 02472
- Web
- https://www.eloxxpharma.com/
- Phone
- +1 7815775300
- Contact
- John Woolford
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ELOX
Similar to ELOX
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Eloxx Pharmaceuticals share price?
As of Today at 14:26 UTC, shares in Eloxx Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Eloxx Pharmaceuticals share price performed this year?
Shares in Eloxx Pharmaceuticals last closed at $0.00 and the price had moved by -99.99% over the past 365 days. In terms of relative price strength the Eloxx Pharmaceuticals share price has underperformed the S&P500 Index by -99.99% over the past year.
What are the analyst and broker recommendations for Eloxx Pharmaceuticals?
The overall consensus recommendation for Eloxx Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Eloxx Pharmaceuticals dividend yield?
Eloxx Pharmaceuticals does not currently pay a dividend.
Does Eloxx Pharmaceuticals pay a dividend?
Eloxx Pharmaceuticals does not currently pay a dividend.
When does Eloxx Pharmaceuticals next pay dividends?
Eloxx Pharmaceuticals does not currently pay a dividend.
How do I buy Eloxx Pharmaceuticals shares?
To buy shares in Eloxx Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eloxx Pharmaceuticals?
As of the previous close price of $0.00, shares in Eloxx Pharmaceuticals had a market capitalisation of $0.00m.
Where are Eloxx Pharmaceuticals shares listed?
Here are the trading details for Eloxx Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ELOX
What kind of share is Eloxx Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Eloxx Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eloxx Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Eloxx Pharmaceuticals is $30.00. That is 29999900% above the last closing price of $0.00.
Analysts covering Eloxx Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$7.45 for the next financial year.
Find out moreWhat is the trend in the Eloxx Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eloxx Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -49.87%.
As of the last closing price of $0.00, shares in Eloxx Pharmaceuticals were trading -99.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eloxx Pharmaceuticals PE Ratio?
The Eloxx Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals' management team is headed by:
- Tomer Kariv - NEC
- Sumit Aggarwal - PRE
- Daniel Geffken - CFO
- Ali Hariri - OTH
- Vijay Modur - OTH
- Zafrira Avnur - IND
- Ran Nussbaum - IND
- Rajesh Parekh - IND
- Steven Rubin - IND
- Jasbir Seehra - IND
- Gadi Veinrib - IND
- Alan Walts - IND